CAR-NK

CAR-NK cells
Other namesChimeric antigen receptor natural killer cells
UsesCancer immunotherapy, hematologic malignancies, solid tumors

CAR-NK cells (chimeric antigen receptor natural killer cells) are an emerging form of cellular immunotherapy for cancer. Researchers engineer natural killer (NK) cells, innate immune effectors, to express chimeric antigen receptors (CARs) that target specific tumor-associated antigens.[1] Unlike CAR-T cells, CAR-NK cells offer advantages such as reduced risk of cytokine release syndrome (CRS) and graft-versus-host disease (GVHD), enabling "off-the-shelf" allogeneic use.[2] As of 2025, CAR-NK therapies show promise in hematologic malignancies and solid tumors, with ongoing trials exploring their potential in autoimmune diseases.[1]

Natural killer cells

Natural killer (NK) cells form part of the innate immune system, recognizing and lysing abnormal cells without prior sensitization.[1] They express activating and inhibitory receptors, balancing cytotoxicity against healthy cells.[3] In cancer, NK cells target tumor cells via stress ligands, but tumors evade detection through MHC class I upregulation and immunosuppressive microenvironments. CAR technology, adapted from T-cell therapies, equips NK cells with synthetic receptors for antigen-specific targeting.[1] CAR-NK cells retain NK-specific killing mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and cytokine release, complementing CAR-mediated lysis.[4] This dual action enhances efficacy against heterogeneous tumors.[1]

History

CAR-NK therapy evolved from CAR-T successes in hematologic cancers.[5] Early challenges included NK cell expansion and transduction efficiency.[2] Researchers optimized CAR constructs for NK cells, incorporating NKG2D or CD16 proteins for enhanced activation.[6] CAR generations adapted for NK cells include second-generation constructs with 4-1BB or 2B4 costimulatory domains for persistence.[2] Third-generation CARs add IL-15 for autocrine signaling, enhancing expansion. Safety switches such as inducible caspase 9 enable controlled elimination.[1]

Fourth-generation CAR-NK cells target IL-12 for solid tumors.[1] iPSC platforms promise universal donors.[7] Combination with PD-1 inhibitors enhances efficacy by 25% in preclinical models.[8] By 2030, CAR-NK may treat 20% of refractory cancers.[1]

As of 2025, 124 clinical trials were investigating CAR-NK cells, targeting 36 diseases, targeting both hematologic (54%) and solid (34%) tumors.[1]

Mechanism of action

CAR-NK cells express a synthetic receptor comprising an extracellular antigen-binding domain (scFv), transmembrane hinge, and intracellular signaling domain (CD3ζ, costimulatory molecules).[9] Upon antigen binding, the CAR triggers NK activation, releasing perforin and granzymes for lysis, and cytokines like IFN-γ for tumor microenvironment modulation.[6] Unlike CAR-T cells, CAR-NK retain ADCC via CD16 and NKG2D-mediated killing, providing multi-pathway antitumor effects.[10] They also inhibit tumor growth via FasL and TRAIL.[2] In solid tumors, CAR-NK cells overcome immunosuppressive environments by secreting IL-15, promoting persistence and recruiting other effectors.[11] Preclinical models show CAR-NK efficacy against CD19+ lymphomas and HER2+ breast cancer.[12]

Sources

Natural killer cells derive from various sources, each with unique advantages.[1] Sources include peripheral blood, cord blood, induced pluripotent stem cells (iPSCs), and NK-92 lines.[1]

Peripheral blood

Peripheral blood mononuclear cells (PBMCs) yield autologous or allogeneic natural killer cells, offering rapid isolation but limited expansion.[2] They express high CD16 for ADCC.[13]

Cord blood

Umbilical cord blood provides naive NK cells with high proliferative potential and low alloreactivity.[14] A phase 1 trial used cord blood cells against CD19+ B-cell malignancies, achieving complete remission in 73% of patients without CRS or neurotoxicity.[15]

Induced pluripotent stem cells

iPSC-derived CAR-NK cells enable scalable, standardized production.[1] iPSCs enable unlimited supply of standardized CAR-NK cells, free from donor variability. They differentiate into NK-like cells expressing high-affinity receptors. Preclinical studies demonstrate efficacy against leukemia without toxicity.[7]

NK cell lines

The NK-92 line, irradiated for safety, transduces efficiently but requires repeated dosing due to lack of persistence.[16] Clinical trials targeted solid tumors like ovarian cancer.[2]

Clinical trials

As of October 2025, 124 CAR-NK trials targeted 36 diseases, both hematologic malignancies (54%) and solid tumors (34%).[1] Initial trials report high response rates and low toxicity.[17]

Hematologic malignancies

A phase 1/2 trial of cord blood CAR-NK cells targeting CD19 in non-Hodgkin lymphoma and CLL achieved 73% overall response rate, with 64% complete remission and no severe CRS.[18] Median remission lasted 9 months.[19] NK-92-derived CAR-NK cells against BCMA in multiple myeloma showed 50% response in phase 1.[20]

Solid tumors

Trials target HER2 in breast cancer and GD2 in neuroblastoma, with preclinical efficacy but limited persistence.[21] A phase 1 trial of iPSC-derived CAR-NK cells against GD2 in neuroblastoma reported 40% stable disease.[7] For ovarian cancer, NK-92 CAR-NK cells against MUC16 showed tumor reduction in xenografts.[22] In 2025, a phase 1 trial of CAR-NK cells targeting CLDN18.2 in gastric cancer achieved 60% objective response rate.[1]

Autoimmune diseases

Early trials explore CAR-NK cells for lupus and rheumatoid arthritis, targeting autoreactive B cells without broad immunosuppression.[1]

Comparison with CAR-T cells

CAR-NK cells avoid CRS and neurotoxicity, with incidence below 5% versus 80% in CAR-T trials.[23] Allogeneic CAR-NK cells lack HLA matching requirements, reducing GVHD risk to zero.[2] They bridge innate and adaptive immunity, killing via multiple pathways. Products can be manufactured from iPSCs, rather than customized for each patient, cutting costs by 50% compared to autologous CAR-T.[24] Persistence averages 1–3 months, sufficient for hematologic responses but requiring optimization for solids.[25]

Challenges

NK cells expand less efficiently than T cells, limiting doses to 10^9 cells.[2] Tumor microenvironments suppress CAR-NK via TGF-β, reducing infiltration.[26] Antigen escape occurs in 20–30% of cases. In 2025, trials reported 15% manufacturing failure due to transduction variability.[1] Strategies include armored CARs secreting IL-15 and checkpoint inhibitors.[27]

See also

References

  1. ^ a b c d e f g h i j k l m n o p Chen, Sisi; Zhang, Lei; He, Xin; Li, Zhongjun (2025). "The clinical landscape of CAR NK cells". Experimental Hematology & Oncology. 14 (1): 46. doi:10.1186/s40164-025-00633-8. PMC 11951618. PMID 40149002.
  2. ^ a b c d e f g h Zhang, Leisheng; Meng, Yuan; Feng, Xiaoming; Han, Zhongchao (2022-03-18). "CAR-NK cells for cancer immunotherapy: from bench to bedside". Biomarker Research. 10 (1): 12. doi:10.1186/s40364-022-00364-6. ISSN 2050-7771. PMC 8932134. PMID 35303962.
  3. ^ Vivier, Eric; Tomasello, Elena; Baratin, Myriam; Walzer, Thierry; Ugolini, Sophie (May 2008). "Functions of natural killer cells". Nature Immunology. 9 (5): 503–510. doi:10.1038/ni1582. ISSN 1529-2916. PMID 18425107.
  4. ^ Balkhi, Sahar; Zuccolotto, Gaia; Di Spirito, Anna; Rosato, Antonio; Mortara, Lorenzo (2025-04-07). "CAR-NK cell therapy: promise and challenges in solid tumors". Frontiers in Immunology. 16 1574742. doi:10.3389/fimmu.2025.1574742. ISSN 1664-3224. PMC 12009813. PMID 40260240.
  5. ^ Peng, Lei; Sferruzza, Giacomo; Yang, Luojia; Zhou, Liqun; Chen, Sidi (October 2024). "CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors". Cellular & Molecular Immunology. 21 (10): 1089–1108. doi:10.1038/s41423-024-01207-0. ISSN 2042-0226. PMC 11442786. PMID 39134804.
  6. ^ a b Chen, Mengmeng; Zhang, Bing; Mu, Xuanlin; Zhang, Bingqiang; Yang, Tielin; Zhang, Gaofeng; Gu, Yuchao; Pei, Bin; Liang, Shaoshuai (2025). "Recent advances in tumor immunotherapy based on NK cells". Frontiers in Immunology. 16 1595533. doi:10.3389/fimmu.2025.1595533. ISSN 1664-3224. PMC 12367655. PMID 40852706.
  7. ^ a b c Fang, Ying; Chen, Yuning; Li, Yan-Ruide (2025-07-08). "Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform". Stem Cell Reports. 20 (7) 102515. doi:10.1016/j.stemcr.2025.102515. ISSN 2213-6711. PMC 12277817. PMID 40480218.
  8. ^ Liu, Wai Nam; So, Wing Yan; Harden, Sarah L.; Fong, Shin Yie; Wong, Melissa Xin Yu; Tan, Wilson Wei Sheng; Tan, Sue Yee; Ong, Jessica Kai Lin; Rajarethinam, Ravisankar; Liu, Min; Cheng, Jia Ying; Suteja, Lisda; Yeong, Joe Poh Sheng; Iyer, N. Gopalakrishna; Lim, Darren Wan-Teck (2022-11-25). "Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model". Science Advances. 8 (47) eadd1187. Bibcode:2022SciA....8D1187L. doi:10.1126/sciadv.add1187. ISSN 2375-2548. PMC 9683725. PMID 36417514.
  9. ^ Bashiri Dezfouli, Ali; Yazdi, Mina; Pockley, Alan Graham; Khosravi, Mohammad; Kobold, Sebastian; Wagner, Ernst; Multhoff, Gabriele (2021-12-01). "NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development". Cells. 10 (12): 3390. doi:10.3390/cells10123390. ISSN 2073-4409. PMC 8699535. PMID 34943898.
  10. ^ Oelsner, Sarah; Friede, Miriam E.; Zhang, Congcong; Wagner, Juliane; Badura, Susanne; Bader, Peter; Ullrich, Evelyn; Ottmann, Oliver G.; Klingemann, Hans; Tonn, Torsten; Wels, Winfried S. (February 2017). "Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma". Cytotherapy. 19 (2): 235–249. doi:10.1016/j.jcyt.2016.10.009. ISSN 1477-2566. PMID 27887866.
  11. ^ Christodoulou, Ilias; Ho, Won Jin; Marple, Andrew; Ravich, Jonas W.; Tam, Ada; Rahnama, Ruyan; Fearnow, Adam; Rietberg, Cambrynne; Yanik, Sean; Solomou, Elena E.; Varadhan, Ravi; Koldobskiy, Michael A.; Bonifant, Challice L. (December 2021). "Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities". Journal for Immunotherapy of Cancer. 9 (12) e003894. doi:10.1136/jitc-2021-003894. ISSN 2051-1426. PMC 8655609. PMID 34896980.
  12. ^ Zhang, Leisheng; Meng, Yuan; Yao, Hao; Zhan, Rucai; Chen, Shuang; Miao, Wenjing; Ma, Shixun; Xu, Xianghong; Li, Yonghong; Yu, Miao; Han, Yan; Su, Wei; Han, Zhihai; Wang, Tao; Song, Baoquan (2023). "CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future". American Journal of Cancer Research. 13 (11): 5559–5576. ISSN 2156-6976. PMC 10695781. PMID 38058830.
  13. ^ Meng, Fanyi; Zhang, Siqi; Xie, Juan; Zhou, Yuan; Wu, Qingling; Lu, Binyan; Zhou, Shixin; Zhao, Xiangyu; Li, Yang (2023-06-14). "Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells". Journal of Hematology & Oncology. 16 (1): 62. doi:10.1186/s13045-023-01455-z. ISSN 1756-8722. PMC 10265820. PMID 37316891.
  14. ^ Mehta, Rohtesh S.; Shpall, Elizabeth J.; Rezvani, Katayoun (2015). "Cord Blood as a Source of Natural Killer Cells". Frontiers in Medicine. 2: 93. doi:10.3389/fmed.2015.00093. ISSN 2296-858X. PMC 4700256. PMID 26779484.
  15. ^ Liu, Evan; Tongue, Emily; Levin, Susan; Rezvani, Katy; Spitzer, Michael H.; Liu, Enli; Marin, Noelle M.; Basar, Rima; Li, Chun; Wang, Xin; Chen, George; Li, James; Basar, Rima; Leung, Wing; Rezvani, Katy (2020). "Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors". New England Journal of Medicine. 382 (6): 545–553. doi:10.1056/NEJMoa1910607. PMC 7226096. PMID 32023368.
  16. ^ Fabian, Kellsye P.; Hodge, James W. (2021-12-17). "The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy". Molecular Therapy Oncolytics. 23: 266–276. doi:10.1016/j.omto.2021.10.001. ISSN 2372-7705. PMC 8560822. PMID 34761106.
  17. ^ Zhao, Xiaoqian; Xiong, Jian; Li, Danyang; Zhang, Ying (2025). "Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review". Frontiers in Medicine. 12 1655693. doi:10.3389/fmed.2025.1655693. ISSN 2296-858X. PMC 12403998. PMID 40904365.
  18. ^ Release, MD Anderson News. "CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma". MD Anderson Cancer Center. Retrieved 2025-10-12.
  19. ^ MD Anderson News. "CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma". MD Anderson Cancer Center. Retrieved 2025-10-12.
  20. ^ Park, Eunhee; Mun, Hui-Jin; Seo, Eunju; Hwang, Seojin; Lee, Jae Hee; Song, Sukgil; Sung, Hyeran; Kim, Hoi-Yul; Kwon, Mi-Jin (2024-01-22). "CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo". Biomedicines. 12 (1): 248. doi:10.3390/biomedicines12010248. ISSN 2227-9059. PMC 10813548. PMID 38275419.
  21. ^ Gergely, Bence; Vereb, Márk A.; Rebenku, István; Vereb, György; Szöőr, Árpád (2025-02-21). "Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy". Cancers. 17 (5): 731. doi:10.3390/cancers17050731. ISSN 2072-6694. PMC 11898473. PMID 40075578.
  22. ^ Zhang, Xin-Yu; Hong, Lian-Lian; Ling, Zhi-Qiang (2024-05-17). "MUC16: clinical targets with great potential". Clinical and Experimental Medicine. 24 (1): 101. doi:10.1007/s10238-024-01365-5. ISSN 1591-9528. PMC 11101557. PMID 38758220.
  23. ^ Dos Reis, Filipa D.; Saidani, Yanis; Martín-Rubio, Paula; Sanz-Pamplona, Rebeca; Stojanovic, Ana; Correia, Margareta P. (2025). "CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy". Frontiers in Immunology. 16 1603757. doi:10.3389/fimmu.2025.1603757. ISSN 1664-3224. PMC 12162902. PMID 40519903.
  24. ^ Marofi, Faroogh; Al-Awad, Alaa S.; Sulaiman Rahman, Heshu; Markov, Alexander; Abdelbasset, Walid Kamal; Ivanovna Enina, Yulianna; Mahmoodi, Mahnaz; Hassanzadeh, Ali; Yazdanifar, Mahboubeh; Stanley Chartrand, Max; Jarahian, Mostafa (2021). "CAR-NK Cell: A New Paradigm in Tumor Immunotherapy". Frontiers in Oncology. 11 673276. doi:10.3389/fonc.2021.673276. ISSN 2234-943X. PMC 8223062. PMID 34178661. (Retracted, see doi:10.3389/fonc.2023.1285219, PMID 37731635,  Retraction Watch)
  25. ^ Balkhi, Sahar; Zuccolotto, Gaia; Di Spirito, Anna; Rosato, Antonio; Mortara, Lorenzo (2025). "CAR-NK cell therapy: promise and challenges in solid tumors". Frontiers in Immunology. 16 1574742. doi:10.3389/fimmu.2025.1574742. ISSN 1664-3224. PMC 12009813. PMID 40260240.
  26. ^ Shin, Seung hun; Lee, Young Eun; Yoon, Han-Na; Yuk, Chae Min; An, Jun Yop; Seo, Minkoo; Yoon, Sangwon; Oh, Min-Suk; Shin, Sang Chul; Kim, Ji Hyung; Kim, Yong Jun; Kim, Jin-Chul; Kim, Song Cheol; Jang, Mihue (2025-03-01). "An innovative strategy harnessing self-activating CAR-NK cells to mitigate TGF-β1-driven immune suppression". Biomaterials. 314 122888. doi:10.1016/j.biomaterials.2024.122888. ISSN 0142-9612. PMID 39423512.
  27. ^ Daher, May; Basar, Rafet; Gokdemir, Elif; Baran, Natalia; Uprety, Nadima; Nunez Cortes, Ana Karen; Mendt, Mayela; Kerbauy, Lucila Nassif; Banerjee, Pinaki P.; Shanley, Mayra; Imahashi, Nobuhiko; Li, Li; Lim, Francesca Lorraine Wei Inng; Fathi, Mohsen; Rezvan, Ali (2021-02-04). "Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells". Blood. 137 (5): 624–636. doi:10.1182/blood.2020007748. ISSN 1528-0020. PMC 7869185. PMID 32902645.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.